GlassScriptPhysician profile
Vijayveer S Pamar
NPI 1407853963
$49,346.95
in general payments reported to CMS, 2019-2025
67 companies · $8,446 in 2025
The $8,446 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,975 · 2020: $6,200 · 2021: $5,950 · 2022: $7,374 · 2023: $7,000 · 2024: $7,402 · 2025: $8,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Education: $53.79 · Travel and Lodging: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,781.81 |
| Education | $53.79 |
| Travel and Lodging | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $4,887.16 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Mannkind Corporation | $3,901.98 | 2019-2025 | Afrezza |
| Novo Nordisk INC | $3,874.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $3,495.13 | 2019-2024 | Farxiga |
| Tandem Diabetes Care, INC. | $3,237.53 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $2,879.28 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Lilly USA, LLC | $2,599.80 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Cequr Corporation | $2,069.52 | 2022-2025 | Cequr Simplicity |
| Amgen INC. | $1,786.36 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbott Laboratories | $1,554.29 | 2019-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $1,405.08 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,398.69 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $1,322.04 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $1,286.62 | 2019-2025 | |
| Ascensia Diabetes Care US INC. | $1,261.62 | 2023-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $1,208.69 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $1,108.93 | 2019-2025 | Korlym |
| Abbvie INC. | $999.19 | 2019-2025 | |
| Sequel Med Tech, LLC | $834.30 | 2025 | Twiist |
| Beta Bionics, INC. | $763.44 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $675.96 | 2019-2023 | Xyosted, Tlando, Nocdurna |
| Esperion Therapeutics, INC. | $627.58 | 2020-2022 | |
| Recordati_rare_diseases_inc. | $566.71 | 2021-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $563.02 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $468.85 | 2019-2022 | |
| Medtronic Minimed, INC. | $398.51 | 2019-2020 | |
| Valeritas, INC. | $360.14 | 2019 | |
| Insulet Corporation | $332.91 | 2019-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $328.66 | 2022-2025 | Strensiq |
| Kyowa Kirin, INC. | $296.66 | 2023-2025 | Crysvita |
| Zealand Pharma US, INC. | $234.64 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $178.88 | 2020-2022 | |
| Becton, Dickinson and Company | $178.60 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.27 | 2021-2024 | |
| Companion Medical, INC. | $157.23 | 2020 | |
| Madrigal Pharmaceuticals | $152.53 | 2025 | Rezdiffra |
| Grt US Holding, INC. | $127.47 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $117.38 | 2024-2025 | |
| Lifescan, INC. | $111.56 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.60 | 2022-2023 | Cycloset |
| Tolmar, INC. | $95.15 | 2023-2025 | Jatenzo |
| Clarus Therapeutics INC. | $93.18 | 2021 | |
| Shire North American Group INC | $87.01 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $75.90 | 2019 | |
| Janssen Pharmaceuticals, INC | $74.23 | 2019-2020 | |
| Nevro Corp. | $67.84 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $67.02 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $65.80 | 2021-2023 | Somatuline Depot |
| Nestle Healthcare Nutrition INC. | $63.57 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $61.28 | 2023-2025 | Evkeeza, Praluent |
| Averitas Pharma INC. | $58.12 | 2023-2025 | Qutenza |
| Soleno Therapeutics, INC. | $55.62 | 2025 | Vykat Xr |
| Acerus Pharmaceuticals Corporation | $47.33 | 2021-2022 | |
| Almatica Pharma LLC | $46.21 | 2024 | Teriparatide |
| Bigfoot Biomedical INC | $42.10 | 2022 | |
| Eusa Pharma (US) LLC | $40.28 | 2022 | |
| Halozyme INC | $39.26 | 2023 | |
| Ibsa Pharma INC. | $38.44 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $32.30 | 2025 | Imcivree |
| Pfizer INC. | $28.18 | 2024-2025 | |
| Organogenesis INC. | $24.08 | 2022 | |
| Roche Diabetes Care, INC. | $24.03 | 2019 | |
| Chiesi USA, INC. | $21.52 | 2024 | Mycapssa |
| Amryt Pharma Holdings LTD | $18.54 | 2021 | |
| Vivus LLC | $17.63 | 2019-2020 | |
| Horizon Therapeutics Plc | $16.64 | 2020 | |
| Intuity Medical INC | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijayveer Pamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.